The role of antibodies to NMDA-type GluR in CSF was investigated in ES patients.
Significant difference of the antibodies between ES and disease controls was shown.
Predictive value of antibodies for outcome was not confirmed.
GluN2B antibodies were higher especially in ES patients with unknown cause.
We suggested possible contribution of GluN2B antibodies to motor and cognitive outcomes.